Hmmm, according to your link, Bescreened performed a non-clinical trial on a whopping 110 people in 2017, 45 of whom where known to have colorectal cancer. The question is, what have they been doing these last 6 years?
CSIRO do not take products to market. They have retained a 5% interest in Colostat.
Market cap is market cap
100,000 tests is not very many
Colostat at $100 to the end consumer is still very low cost. FIT is $150 and 60% of them end up being thrown out!
Show me another simple blood test that has been through 7 rigorous Australian trials (I.e. highly regulated), is processed on existing lab infrastructure, is 35% more accurate than FIT, even at early stages, and is low cost with or without overhead costs... oh that's right, Colostat!
In my opinion, commercial partners will be quite keen on this product.
- Forums
- ASX - By Stock
- BeScreened
Hmmm, according to your link, Bescreened performed a...
-
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RHY (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.65M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 238342 | 6.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.5¢ | 35319 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 30000 | 0.066 |
2 | 238342 | 0.065 |
2 | 110864 | 0.064 |
1 | 131025 | 0.063 |
2 | 15000 | 0.062 |
Price($) | Vol. | No. |
---|---|---|
0.065 | 35319 | 2 |
0.068 | 1128 | 1 |
0.070 | 86753 | 4 |
0.071 | 150525 | 1 |
0.072 | 2245 | 1 |
Last trade - 09.40am 25/06/2024 (20 minute delay) ? |
Featured News
RHY (ASX) Chart |
Day chart unavailable